Claim 1: the tetravalent antigen complex has a dying activity to OX40, including four antigen binding domains binding to OX40, Each of the four domains contains a variable VH and VL,The complex consists of one or more antigen binding domains, which are combined with the first OX40 subheading and one or more antigen binding domains with the second OX40 subheading, while the first and second OX40 subheadings of OX40 are different. Claim 7: according to any one of the requirements of 1-6, the antigen binding domain binding the first entry of OX40 includes: (a) VH domain, including hvr-h1, including the amino acid sequence of SEQ ID 2,Hvr-h2, including the amino acid sequence of SEQ ID No.3 and hvr-h3, including the amino acid sequence of SEQ ID No.4； and (b) VL domain, including hvr-l1, including the amino acid sequence of SEQ ID No.5, Hvr-l2 includes the amino acid sequence of SEQ ID No.6 and hvr-l3, including the amino acid sequence of SEQ ID No.7. Claim 99: one or more polynucleotides, encoding one or more polypeptides from a complex according to any one claim. Requirement 102: a pharmaceutical formulationA according to any one of the requirements of 1-98, including a complex and a pharmaceutically acceptable carrier. Claim 103: a treatment for cancer patients, including the actual provision of a certain number of complex facilities to individuals in accordance with any one of claims 1-98.Reivindicación 1: Un complejo de unión a antígeno tetravalente que tiene actividad agonista para OX40, donde el complejo comprende cuatro dominios de unión a antígeno que se unen con OX40, en donde cada uno de los cuatro dominios de unión a antígeno comprende un dominio variable de cadena pesada de anticuerpo (VH) y un dominio variable de cadena liviana de anticuerpo (VL), en donde el complejo comprende uno o varios dominios de unión a antígeno que se unen con un primer epítope de OX40 y uno o varios dominios de unión a antígeno que se unen con un segundo epítope de OX40 y en donde
